



hVIVO plc
("hVIVO" or the "Company")

Finance Director

London, UK – 31 July 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral challenge, announces that Shelley Fraser, Finance Director and Company Secretary, is leaving hVIVO.

The Board has appointed Anesh Patel as Interim Finance Director and Company Secretary with immediate effect. A further announcement will be made in due course to confirm the appointment of Shelley's successor.

Anesh was previously Director, Corporate Finance at hVIVO, a role he has held since April 2016. Prior to this he spent seven years in investment banking providing corporate finance advisory services to a range of clients having started his professional career with Ernst & Young in 2004 where he qualified as a Chartered Accountant. He graduated from University College London (UCL) and holds an MSc (Hons) degree in Mathematics with Economics.

Dr Trevor Phillips, Executive Chairman, commented:

"On behalf of the Board I would like to thank Shelley for her contribution to the Company and we wish her success in the future. We are pleased to be able to appoint Anesh as interim Finance Director who has worked at the Company for a number of years and worked closely with Shelley and the Finance team to ensure a smooth and effective transition."

For further information please contact:

hVIVO plc

Trevor Phillips (Executive Chairman)

+44 207 756 1300

Fleur Wood (EVP, Investor Relations & Communications)

Numis Securities Limited

+44 207 260 1000

Freddie Barnfield / Huw Jeremy (Nominated Adviser)

James Black (Corporate Broking)

FTI Consulting

Simon Conway / Victoria Foster Mitchell

+44 203 727 1000

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.